{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:21:28Z","timestamp":1788272488128,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00951-9","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:29:33Z","timestamp":1787628573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CUDC-907 attenuates pulmonary fibrosis by reversing HDAC1-mediated SMAD4 deacetylation at lysine 45"],"prefix":"10.1186","volume":"21","author":[{"given":"Yu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenye","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhike","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-7173","authenticated-orcid":false,"given":"Chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"10082","key":"951_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941\u201352.","journal-title":"Lancet"},{"issue":"9807","key":"951_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TE King Jr","year":"2011","unstructured":"King TE Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949\u201361.","journal-title":"Lancet"},{"issue":"3","key":"951_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"key":"951_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss BJ, Ryter SW, Rosas IO. Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis. Annu Rev Pathol. 2022;17:515\u201346.","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"951_CR5","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1172\/JCI60323","volume":"122","author":"PW Noble","year":"2012","unstructured":"Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;122(8):2756\u201362.","journal-title":"J Clin Invest"},{"key":"951_CR6","doi-asserted-by":"publisher","first-page":"104766","DOI":"10.1016\/j.ebiom.2023.104766","volume":"95","author":"T Karampitsakos","year":"2023","unstructured":"Karampitsakos T, Juan-Guardela BM, Tzouvelekis A, Herazo-Maya JD. Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine. 2023;95:104766.","journal-title":"EBioMedicine"},{"issue":"9779","key":"951_CR7","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet"},{"issue":"22","key":"951_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"1","key":"951_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12931-018-0730-2","volume":"19","author":"G Sgalla","year":"2018","unstructured":"Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19(1):32.","journal-title":"Respir Res"},{"issue":"1","key":"951_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2019.11.027","volume":"180","author":"H Wu","year":"2020","unstructured":"Wu H, Yu Y, Huang H, et al. Progressive Pulmonary Fibrosis Is Caused by Elevated Mechanical Tension on Alveolar Stem Cells. Cell. 2020;180(1):107\u201321. e117.","journal-title":"Cell"},{"key":"951_CR11","doi-asserted-by":"crossref","unstructured":"Cohen ML, Brumwell AN, Ho TC, et al. A fibroblast-dependent TGF-beta1\/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis. J Clin Invest. 2024;134(18).","DOI":"10.1172\/JCI174598"},{"issue":"1","key":"951_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-beta signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104.","journal-title":"Mol Cancer"},{"key":"951_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","volume":"67","author":"J Massague","year":"1998","unstructured":"Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753\u201391.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"951_CR14","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41467-025-56922-7","volume":"16","author":"J Yu","year":"2025","unstructured":"Yu J, Li Y, Li Y, et al. Phosphorylation of FOXN3 by NEK6 promotes pulmonary fibrosis through Smad signaling. Nat Commun. 2025;16(1):1865.","journal-title":"Nat Commun"},{"issue":"10","key":"951_CR15","doi-asserted-by":"publisher","first-page":"9958","DOI":"10.1021\/acs.jmedchem.4c02938","volume":"68","author":"W Cheng","year":"2025","unstructured":"Cheng W, Zheng Y, Tang Q, et al. Discovery of novel cyclic peptides as SMAD2-SMAD4 interaction inhibitors for the Treatment of hepatic fibrosis. J Med Chem. 2025;68(10):9958\u201372.","journal-title":"J Med Chem"},{"issue":"8","key":"951_CR16","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1016\/j.ymthe.2025.04.026","volume":"33","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Zhang TN, Hao PH, Yang N, Du Y. Histone deacetylases and their inhibitors in kidney diseases. Mol Ther. 2025;33(8):3485\u2013527.","journal-title":"Mol Ther"},{"issue":"1","key":"951_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","volume":"39","author":"R Chen","year":"2020","unstructured":"Chen R, Zhang M, Zhou Y, et al. The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res. 2020;39(1):138.","journal-title":"J Exp Clin Cancer Res"},{"key":"951_CR18","first-page":"0953","volume":"8","author":"Y Li","year":"2025","unstructured":"Li Y, Shi X, Zhang F, et al. HDAC11-Mediated Deacetylation of Triosephosphate Isomerase 1 Promotes Idiopathic Pulmonary Fibrosis. Res (Wash D C). 2025;8:0953.","journal-title":"Res (Wash D C)"},{"issue":"15","key":"951_CR19","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.7150\/ijbs.76140","volume":"18","author":"Y Gao","year":"2022","unstructured":"Gao Y, Liu Y, Zheng D, et al. HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation. Int J Biol Sci. 2022;18(15):5724\u201339.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"951_CR20","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"951_CR21","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.semcancer.2020.11.005","volume":"83","author":"B Biersack","year":"2022","unstructured":"Biersack B, Polat S, Hopfner M. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol. 2022;83:472\u201386.","journal-title":"Semin Cancer Biol"},{"key":"951_CR22","doi-asserted-by":"publisher","first-page":"117295","DOI":"10.1016\/j.biopha.2024.117295","volume":"179","author":"SY Zhang","year":"2024","unstructured":"Zhang SY, Zhang LY, Wen R, Yang N, Zhang TN. Histone deacetylases and their inhibitors in inflammatory diseases. Biomed Pharmacother. 2024;179:117295.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"951_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/med.21600","volume":"40","author":"D Tomaselli","year":"2020","unstructured":"Tomaselli D, Lucidi A, Rotili D, Mai A. Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med Res Rev. 2020;40(1):190\u2013244.","journal-title":"Med Res Rev"},{"issue":"9","key":"951_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41419-020-02916-w","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhang Y, Tu T, et al. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFbeta1 induced lung and tumor fibrosis. Cell Death Dis. 2020;11(9):765.","journal-title":"Cell Death Dis"},{"issue":"5","key":"951_CR25","first-page":"1789","volume":"44","author":"T Tu","year":"2019","unstructured":"Tu T, Huang J, Lin M, et al. CUDC\u2013907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K\/Akt\/mTOR signaling and HDAC2. Int J Mol Med. 2019;44(5):1789\u2013800.","journal-title":"Int J Mol Med"},{"issue":"4","key":"951_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/1759-7714.15196","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Pan B, Zhang F, et al. TPI1 promotes MAPK\/ERK-induced EMT, cell migration and invasion in lung adenocarcinoma. Thorac Cancer. 2024;15(4):327\u201338.","journal-title":"Thorac Cancer"},{"issue":"20","key":"951_CR27","doi-asserted-by":"publisher","first-page":"e2100014","DOI":"10.1002\/advs.202100014","volume":"8","author":"B Yu","year":"2021","unstructured":"Yu B, Luo F, Sun B, et al. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer. Adv Sci (Weinh). 2021;8(20):e2100014.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"951_CR28","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1038\/s41467-022-34831-3","volume":"13","author":"A Osseni","year":"2022","unstructured":"Osseni A, Ravel-Chapuis A, Belotti E, et al. Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-beta via Smad3 acetylation. Nat Commun. 2022;13(1):7108.","journal-title":"Nat Commun"},{"key":"951_CR29","doi-asserted-by":"crossref","unstructured":"Liu L, Li Q, Yang L, Li Q, Du X. SMAD4 Feedback activates the canonical TGF-beta family signaling pathways. Int J Mol Sci. 2021;22(18).","DOI":"10.3390\/ijms221810024"},{"issue":"17","key":"951_CR30","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41388-026-03752-6","volume":"45","author":"S Wang","year":"2026","unstructured":"Wang S, Tong X, Sun R, et al. STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4. Oncogene. 2026;45(17):1530\u201343.","journal-title":"Oncogene"},{"issue":"12","key":"951_CR31","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/nar\/28.12.2363","volume":"28","author":"JB Jones","year":"2000","unstructured":"Jones JB, Kern SE. Functional mapping of the MH1 DNA-binding domain of DPC4\/SMAD4. Nucleic Acids Res. 2000;28(12):2363\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"951_CR32","doi-asserted-by":"publisher","first-page":"8124","DOI":"10.1021\/acs.jmedchem.4c02550","volume":"68","author":"M Yang","year":"2025","unstructured":"Yang M, Zhao W, Zhang J, et al. HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation. J Med Chem. 2025;68(8):8124\u201342.","journal-title":"J Med Chem"},{"issue":"6","key":"951_CR33","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1021\/acs.jmedchem.5c03107","volume":"69","author":"Q Chai","year":"2026","unstructured":"Chai Q, Yang M, Liu C, et al. Discovery of a Hydroxamic Acid-Based HDAC11 Isoform-Selective Inhibitor with Oral Anti-AML Potency. J Med Chem. 2026;69(6):6816\u201334.","journal-title":"J Med Chem"},{"key":"951_CR34","doi-asserted-by":"publisher","first-page":"178260","DOI":"10.1016\/j.ejphar.2025.178260","volume":"1007","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Li J, Wang Q, et al. CUDC-907 inhibits osteosarcoma through upregulation of PTX3 and inhibition of PI3K-AKT signaling. Eur J Pharmacol. 2025;1007:178260.","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"951_CR35","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1111\/jcmm.15281","volume":"24","author":"C Hu","year":"2020","unstructured":"Hu C, Xia H, Bai S, et al. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. J Cell Mol Med. 2020;24(13):7239\u201353.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"951_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(15)00584-7","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Berdeja JG, Patel MR, et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016;17(5):622\u201331.","journal-title":"Lancet Oncol"},{"issue":"2","key":"951_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/bjh.17730","volume":"195","author":"DJ Landsburg","year":"2021","unstructured":"Landsburg DJ, Barta SK, Ramchandren R, et al. Fimepinostat (CUDC-907) in patients with relapsed\/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol. 2021;195(2):201\u20139.","journal-title":"Br J Haematol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00951-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00951-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00951-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:57:32Z","timestamp":1788271052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00951-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00951-9","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All mouse experiment procedures and protocols were evaluated and authorized by the Soochow University Laboratory Animal Center and the Animal Ethics Committee of Soochow University (approval number: 202311A0273). All procedures were executed in compliance with the ARRIVE guidelines and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"158"}}